A Randomized, Double-blind, Placebo-controled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Trial Profile

A Randomized, Double-blind, Placebo-controled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Eluxadoline (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms IBS-3001
  • Sponsors Furiex Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2017 Results of pooled post hoc analysis of IBS-3001 and IBS-3002 trials assessing responder and non-responder rates over 4-week intervals and the proportion of responders/non-responders who continued or discontinued treatment presented at the 25th United European Gastroenterology Week
    • 01 Nov 2017 Results (n=2423) of pooled post hoc analysis of IBS-3001 and IBS-3002 trials evaluating consecutive weeks of inadequate relief presented at the 25th United European Gastroenterology Week
    • 10 Jul 2017 Accoring to an Allergan media release, the company reported result of pooled subgroup analysis of two phase III trials (IBS-3001 and IBS-3002).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top